NEW YORK (GenomeWeb News) – Metabolon will collaborate with a group of European research centers to find biomarkers that are related to insulin resistance in an effort to develop a test that could detect diabetes before an individual has the disease.
Under the collaboration, Metabolon said it will discover and validate biomarkers from samples collected from studies conducted at 19 different clinical research centers that are members of the European Group for the Study of Insulin Resistance.
Insulin resistance generally is an asymptomatic condition that can precede the arrival of type 2 diabetes, and it is estimated to affect around one-third of the adult population in the US, or around 75 million people, the company said.
The company plans to use the research to speed up development of its Quantose test for screening of pre-diabetic patients.
Metabolon CEO John Ryals said the “routine test will help identify pre-diabetic patients years before they become diabetic,” and that it could be used to help doctors “intervene with lifestyle or drug therapies which may delay or prevent the onset of type 2 diabetes.”
Financial terms of the collaboration were not released.